Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis. | Clin Exp Med | 2023 | 35913675 | PubTator, text mining | PubMed |
| Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). | J Clin Oncol | 2023 | 35737919 | PubTator, text mining | PubMed |
| Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. | Cancer Res Treat | 2023 | 35681111 | PubTator, text mining | PubMed |
| Characterization of rare histological subtypes of ovarian cancer based on molecular profiling. | Cancer Med | 2023 | 35676859 | PubTator, text mining | PubMed |
| Histone H2A variants: Diversifying chromatin to ensure genome integrity. | Semin Cell Dev Biol | 2023 | 35331626 | PubTator, text mining | PubMed |
| DriverMP enables improved identification of cancer driver genes. | Gigascience | 2022 | 38091511 | PubTator, text mining | PubMed |
| Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers. | Cancer Innov | 2022 | 38089758 | PubTator, text mining | PubMed |
| Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. | Cancer Res Commun | 2022 | 36970052 | PubTator, text mining | PubMed |
| Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry. | Cancer Res Commun | 2022 | 36922933 | PubTator, text mining | PubMed |
| Diagnosis of triple negative breast cancer using expression data with several machine learning tools. | Bioinformation | 2022 | 36909691 | PubTator, text mining | PubMed |
| Identification of NLE1/CDK1 axis as key regulator in the development and progression of non-small cell lung cancer. | Front Oncol | 2022 | 36818671 | PubTator, text mining | PubMed |
| Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine. | Front Oncol | 2022 | 36741700 | PubTator, text mining | PubMed |
| SDHB exon 1 deletion: A recurrent germline mutation in Colombian patients with pheochromocytomas and paragangliomas. | Front Genet | 2022 | 36685941 | PubTator, text mining | PubMed |
| Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study. | Genes (Basel) | 2022 | 36672847 | PubTator, text mining | PubMed |
| Bioinformatics analysis of the prognostic biomarkers and predictive accuracy of differentially expressed genes in high-risk multiple myeloma based on Gene Expression Omnibus database mining. | Ann Transl Med | 2022 | 36660705 | PubTator, text mining | PubMed |
| Clinical features and long-term outcomes of patients with colonic oligopolyposis of unknown etiology. | World J Gastroenterol | 2022 | 36632322 | PubTator, text mining | PubMed |
| Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment. | Cancers (Basel) | 2022 | 36612210 | PubTator, text mining | PubMed |
| Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. | Cancers (Basel) | 2022 | 36612206 | PubTator, text mining | PubMed |
| Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma. | Cancers (Basel) | 2022 | 36612198 | PubTator, text mining | PubMed |
| Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! | Cancers (Basel) | 2022 | 36612041 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=39